Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Current Taxes (2019 - 2025)

Historic Current Taxes for Ligand Pharmaceuticals (LGNYZ) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • Ligand Pharmaceuticals' Current Taxes fell 3908.92% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 3908.92%. This contributed to the annual value of $1.2 million for FY2024, which is N/A changed from last year.
  • Ligand Pharmaceuticals' Current Taxes amounted to $1.3 million in Q3 2025, which was down 3908.92% from $305000.0 recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Current Taxes high stood at $11.4 million for Q2 2023, and its period low was $305000.0 during Q2 2025.
  • In the last 4 years, Ligand Pharmaceuticals' Current Taxes had a median value of $1.9 million in 2024 and averaged $3.5 million.
  • Over the last 5 years, Ligand Pharmaceuticals' Current Taxes had its largest YoY gain of 20108.41% in 2023, and its largest YoY loss of 8759.15% in 2023.
  • Quarter analysis of 4 years shows Ligand Pharmaceuticals' Current Taxes stood at $9.7 million in 2022, then crashed by 87.59% to $1.2 million in 2023, then decreased by 0.42% to $1.2 million in 2024, then grew by 7.09% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $305000.0 for Q2 2025, and $1.8 million during Q1 2025.